Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s management team will participate in the 30 th Annual Piper Jaffray Healthcare Conference in New York :
View HTML
Toggle Summary Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of November 6, 2018 , under
View HTML
Toggle Summary Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018
A comprehensive suite of innovative immuno-oncology applications to improve the future of cancer care SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technology, is showcasing its latest innovations for
View HTML
Toggle Summary Fluidigm Recognized as a Company to Watch in 2019
Immuno-oncology innovator receives life science people’s choice award SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- BioInformatics Inc. , the leading research and advisory firm serving the life science tool market, today announced Fluidigm as the Company to Watch in 2019 at the
View HTML
Toggle Summary Fluidigm Announces Third Quarter 2018 Financial Results
Total revenue increases 17 percent to $29.0 million Mass cytometry revenue growth of 50 percent Instrument revenue growth of 32 percent SOUTH SAN FRANCISCO, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the third quarter ended
View HTML
Toggle Summary Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sirona Dx, a leader in high-complexity genomics and proteomics services, today announced the introduction of
View HTML
Toggle Summary Laura Clague Named to Fluidigm Board of Directors
Senior Financial Leader with Broad Corporate and Biotech Expertise SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Laura M. Clague to the company’s Board of Directors and its audit committee.
View HTML
Toggle Summary Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System
Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technology, today
View HTML
Toggle Summary Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD
Combining high-performance automated microfluidics with easy-to-use software to streamline CNV detection for translational and clinical research SOUTH SAN FRANCISCO, Calif. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report third quarter financial results on Thursday, November 1, 2018 , after the close of the market.
View HTML